Cargando…

Integrative metabolomic characterisation identifies altered portal vein serum metabolome contributing to human hepatocellular carcinoma

OBJECTIVE: Altered metabolites are important for the tumourigenicity of hepatocellular carcinoma (HCC). We performed integrative metabolomics analysis of the metabolites changes in portal venous blood and in comparison with the metabolites changes in liver tissues and stool samples of HCC patients a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jinkai, Geng, Wei, Sun, Hanyong, Liu, Changan, Huang, Fan, Cao, Jie, Xia, Lei, Zhao, Hongchuan, Zhai, Jianning, Li, Qing, Zhang, Xiang, Kuang, Ming, Shen, Shunli, Xia, Qiang, Wong, Vincent Wai-Sun, Yu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120406/ https://www.ncbi.nlm.nih.gov/pubmed/34344785 http://dx.doi.org/10.1136/gutjnl-2021-325189

Ejemplares similares

Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas
por: Amaddeo, Giuliana, et al.
Publicado: (2015)

Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET)
por: Weiss, Emmanuel, et al.
Publicado: (2023)

Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma
por: Tortora, Raffaella, et al.
Publicado: (2023)

A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis
por: Xing, Yueyi, et al.
Publicado: (2022)

Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial
por: Qi, Xingshun, et al.
Publicado: (2013)

Evaluating clinical outcomes and prognosis in patients with cirrhosis and portal hypertension: a retrospective observational cohort study
por: Lee, Nerissa Hoi Ching, et al.
Publicado: (2023)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Portal vein thrombosis after donor liver biopsy: Case report
por: Bashir, Shahnawaz, et al.
Publicado: (2018)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
por: Xiong, Zhewen, et al.
Publicado: (2023)

Characterisation of liver pathogenesis, human immune responses and drug testing in a humanised mouse model of HCV infection
por: Keng, Choong Tat, et al.
Publicado: (2016)

The microtubule-associated protein PRC1 promotes early recurrence of hepatocellular carcinoma in association with the Wnt/β-catenin signalling pathway
por: Chen, Jianxiang, et al.
Publicado: (2016)

PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma
por: Lu, Li-Gong, et al.
Publicado: (2022)

From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification
por: Fan, Zhongqi, et al.
Publicado: (2023)

Predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis
por: Wang, Peng, et al.
Publicado: (2023)

Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis
por: Li, Tong, et al.
Publicado: (2016)

Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
por: Shang, Runze, et al.
Publicado: (2021)

Serum metabolomic profiling reveals an increase in homocitrulline in Chinese patients with nonalcoholic fatty liver disease: a retrospective study
por: Yang, Yarong, et al.
Publicado: (2021)

Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma
por: Cai, Jiabin, et al.
Publicado: (2019)

STK33 promotes hepatocellular carcinoma through binding to c-Myc
por: Yang, Tian, et al.
Publicado: (2016)

Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma
por: Jühling, Frank, et al.
Publicado: (2021)

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
por: Chan, Tim Hon Man, et al.
Publicado: (2014)

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis
por: Lee, Sung Won, et al.
Publicado: (2020)

Keratin 19: a key role player in the invasion of human hepatocellular carcinomas
por: Govaere, Olivier, et al.
Publicado: (2014)

Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis
por: Lee, Jun Ho, et al.
Publicado: (2019)

Postoperative adjuvant transarterial chemoembolisation improves survival of hepatocellular carcinoma patients with microvascular invasion: A multicenter retrospective cohort
por: Luo, Laihui, et al.
Publicado: (2023)

Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma
por: Garnelo, Marta, et al.
Publicado: (2017)

Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?
por: Tholey, Danielle M, et al.
Publicado: (2017)

Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage
por: Perugorria, Maria J, et al.
Publicado: (2019)

TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms
por: Esparza-Baquer, Aitor, et al.
Publicado: (2021)

Cost of hepatocellular carcinoma to the national health service in England: a registry-based analysis
por: Cullen, Katherine, et al.
Publicado: (2023)

Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2019)

Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas
por: Zhang, Qi, et al.
Publicado: (2019)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

von Willebrand factor as a biomarker of clinically significant portal hypertension and severe portal hypertension: a systematic review and meta-analysis
por: Zou, Ziyuan, et al.
Publicado: (2019)

Acute kidney injury after multiphase imaging for lesions detected on hepatocellular carcinoma surveillance in patients with cirrhosis
por: Khan, Adnan Aman, et al.
Publicado: (2020)

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
por: Chew, Valerie, et al.
Publicado: (2011)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study
por: De Toni, Enrico N, et al.
Publicado: (2020)

A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study
por: Zhou, Zheyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ekjjsnj8b2unkmo1odmpeegfvs